G1 Therapeutics Future Growth
Future criteria checks 6/6
G1 Therapeutics is forecast to grow earnings and revenue by 55.1% and 23.1% per annum respectively. EPS is expected to grow by 55.6% per annum. Return on equity is forecast to be 69.3% in 3 years.
Key information
55.1%
Earnings growth rate
55.6%
EPS growth rate
Biotechs earnings growth | 31.5% |
Revenue growth rate | 23.1% |
Future return on equity | 69.3% |
Analyst coverage | Low |
Last updated | 24 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 348 | 187 | 965 | 496 | 5 |
12/31/2025 | 102 | -21 | 21 | -7 | 5 |
12/31/2024 | 69 | -38 | 10 | -36 | 5 |
12/31/2023 | 83 | -48 | -38 | -38 | N/A |
9/30/2023 | 78 | -71 | -56 | -56 | N/A |
6/30/2023 | 89 | -78 | -67 | -67 | N/A |
3/31/2023 | 57 | -126 | -120 | -119 | N/A |
12/31/2022 | 51 | -148 | -129 | -129 | N/A |
9/30/2022 | 47 | -154 | -133 | -133 | N/A |
6/30/2022 | 28 | -171 | -146 | -145 | N/A |
3/31/2022 | 24 | -171 | -143 | -143 | N/A |
12/31/2021 | 31 | -148 | -132 | -132 | N/A |
9/30/2021 | 42 | -134 | -129 | -129 | N/A |
6/30/2021 | 64 | -103 | -91 | -91 | N/A |
3/31/2021 | 60 | -95 | -84 | -84 | N/A |
12/31/2020 | 45 | -99 | -84 | -84 | N/A |
9/30/2020 | 29 | -109 | -83 | -82 | N/A |
6/30/2020 | 2 | -130 | -113 | -111 | N/A |
3/31/2020 | N/A | -130 | -108 | -105 | N/A |
12/31/2019 | N/A | -122 | -102 | -100 | N/A |
9/30/2019 | N/A | -111 | -93 | -91 | N/A |
6/30/2019 | N/A | -99 | -83 | -82 | N/A |
3/31/2019 | N/A | -89 | -79 | -78 | N/A |
12/31/2018 | N/A | -85 | -75 | -74 | N/A |
9/30/2018 | N/A | -78 | -68 | -68 | N/A |
6/30/2018 | N/A | -74 | -65 | -65 | N/A |
3/31/2018 | N/A | -68 | -60 | -59 | N/A |
12/31/2017 | N/A | -65 | -51 | -51 | N/A |
9/30/2017 | N/A | -60 | N/A | -45 | N/A |
6/30/2017 | N/A | -52 | N/A | -37 | N/A |
3/31/2017 | N/A | -45 | N/A | -29 | N/A |
12/31/2016 | N/A | -35 | N/A | -25 | N/A |
12/31/2015 | 1 | -22 | N/A | -14 | N/A |
12/31/2014 | 1 | -7 | N/A | -6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: G1H is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.7%).
Earnings vs Market: G1H is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: G1H is expected to become profitable in the next 3 years.
Revenue vs Market: G1H's revenue (23.1% per year) is forecast to grow faster than the German market (5.5% per year).
High Growth Revenue: G1H's revenue (23.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: G1H's Return on Equity is forecast to be very high in 3 years time (69.3%).